David Hoang
Stock Analyst at Citigroup
(4.04)
# 327
Out of 4,667 analysts
31
Total ratings
55.56%
Success rate
13.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $30 → $23 | $16.27 | +41.36% | 4 | Aug 8, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $176 → $160 | $110.86 | +44.33% | 5 | Aug 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $150 → $158 | $123.29 | +28.15% | 4 | Aug 2, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $26 → $32 | $24.42 | +31.04% | 2 | Aug 2, 2024 | |
| LBPH Longboard Pharmaceuticals | Maintains: Buy | $45 → $50 | $59.77 | -16.35% | 3 | Aug 2, 2024 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $7 | $2.37 | +195.36% | 1 | Jul 25, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $32.79 | +46.39% | 1 | Jun 21, 2024 | |
| SAGE Sage Therapeutics | Initiates: Sell | $8 | $4.91 | +62.93% | 1 | May 29, 2024 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $62 → $60 | $39.34 | +52.52% | 2 | May 10, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $127 → $125 | $94.60 | +32.14% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.96 | +222.58% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.36 | +198.51% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $248.79 | -11.57% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $18.71 | +327.58% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $0.70 | +330.73% | 1 | Dec 7, 2022 |
ACADIA Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $30 → $23
Current: $16.27
Upside: +41.36%
Sarepta Therapeutics
Aug 8, 2024
Maintains: Neutral
Price Target: $176 → $160
Current: $110.86
Upside: +44.33%
Neurocrine Biosciences
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $123.29
Upside: +28.15%
Denali Therapeutics
Aug 2, 2024
Maintains: Buy
Price Target: $26 → $32
Current: $24.42
Upside: +31.04%
Longboard Pharmaceuticals
Aug 2, 2024
Maintains: Buy
Price Target: $45 → $50
Current: $59.77
Upside: -16.35%
Acumen Pharmaceuticals
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $2.37
Upside: +195.36%
Harmony Biosciences Holdings
Jun 21, 2024
Initiates: Buy
Price Target: $48
Current: $32.79
Upside: +46.39%
Sage Therapeutics
May 29, 2024
Initiates: Sell
Price Target: $8
Current: $4.91
Upside: +62.93%
Xenon Pharmaceuticals
May 10, 2024
Maintains: Buy
Price Target: $62 → $60
Current: $39.34
Upside: +52.52%
Axsome Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $127 → $125
Current: $94.60
Upside: +32.14%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $4.96
Upside: +222.58%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $5.36
Upside: +198.51%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $248.79
Upside: -11.57%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $18.71
Upside: +327.58%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.70
Upside: +330.73%